Recent clinical data (1) suggest that c-erbB-2 overexpression/amplification might be associated with tamoxifen re-sistance in patients with estrogen recep-tor (ER)-positive tumors. This associa-tion is controversial, however, and the question of the efficacy of hormone therapy in these patients is still a matter of debate. In a recent issue of the Jour-nal, Konecny et al. (2) provided some answers to this question. After consider-ing c-erbB-2, ER, and progesterone re-ceptors (PRs) as continuous variables, they reported that patients with higher levels of c-erbB-2 overexpression had statistically significantly lower ER and PR levels than patients with lower levels of c-erbB-2 overexpression. They sug-gested that this finding might explain th...
BACKGROUND: The relationship between quantitative immunohistochemical hormone receptor expression an...
Introduction: Estrogen receptor-a (ER) and human epidermal growth factor receptor 2 (HER2) positivit...
PURPOSE: To evaluate prognostic factors in estrogen receptor (ER)-positive, operable breast cancer f...
Data in the article of Cheang et al. ( 1) help to define relatively high- and low-risk estrogen rece...
"nIntroduction: Breast cancer is the most common malignancy with more than one million new case...
Purpose: Experimental data suggest a complex cross-talk between the HER2 and the estrogen receptor (...
Arpino et al. ( 1) asserted that the antitumor effect of tamoxifen and human epidermal growth factor...
Purpose: To determine the relationship between quantitative estrogen-receptor (ER) and progesterone-...
Numerous studies involving thou-sands of patients have shown that c-erbB2 abnormalities (gene amplif...
PURPOSE: Experimental data suggest a complex cross-talk between HER-2 and estrogen receptor, and it ...
PURPOSE: An association between the overexpression of proto-oncogene HER-2/neu and resistance to tam...
INTRODUCTION: Estrogen receptor-α (ER) and human epidermal growth factor receptor 2 (HER2) positivit...
Introduction: Estrogen receptor-α (ER) and human epidermal growth factor receptor 2 (HER2) positivit...
Data in the article of Cheang et al. ( 1) help to define relatively high- and low-risk estrogen rece...
Aim: HER-2/neu amplification occurs in 15-25% of breast carcinomas. This oncogene, also referred to ...
BACKGROUND: The relationship between quantitative immunohistochemical hormone receptor expression an...
Introduction: Estrogen receptor-a (ER) and human epidermal growth factor receptor 2 (HER2) positivit...
PURPOSE: To evaluate prognostic factors in estrogen receptor (ER)-positive, operable breast cancer f...
Data in the article of Cheang et al. ( 1) help to define relatively high- and low-risk estrogen rece...
"nIntroduction: Breast cancer is the most common malignancy with more than one million new case...
Purpose: Experimental data suggest a complex cross-talk between the HER2 and the estrogen receptor (...
Arpino et al. ( 1) asserted that the antitumor effect of tamoxifen and human epidermal growth factor...
Purpose: To determine the relationship between quantitative estrogen-receptor (ER) and progesterone-...
Numerous studies involving thou-sands of patients have shown that c-erbB2 abnormalities (gene amplif...
PURPOSE: Experimental data suggest a complex cross-talk between HER-2 and estrogen receptor, and it ...
PURPOSE: An association between the overexpression of proto-oncogene HER-2/neu and resistance to tam...
INTRODUCTION: Estrogen receptor-α (ER) and human epidermal growth factor receptor 2 (HER2) positivit...
Introduction: Estrogen receptor-α (ER) and human epidermal growth factor receptor 2 (HER2) positivit...
Data in the article of Cheang et al. ( 1) help to define relatively high- and low-risk estrogen rece...
Aim: HER-2/neu amplification occurs in 15-25% of breast carcinomas. This oncogene, also referred to ...
BACKGROUND: The relationship between quantitative immunohistochemical hormone receptor expression an...
Introduction: Estrogen receptor-a (ER) and human epidermal growth factor receptor 2 (HER2) positivit...
PURPOSE: To evaluate prognostic factors in estrogen receptor (ER)-positive, operable breast cancer f...